CRA evaluates sales in Lanham Act dispute regarding alleged misrepresentations of bioequivalence

CRA assessed whether disputed representations of bioequivalence significantly affected sales of the branded product. CRA’s evaluation included consideration of distribution channels, purchase timing, and the effect of payor control mechanisms on product uptake and sales. The case ultimately resulted in a settlement.

Meet Our Team